# GNE-7915

Cat. No.: HY-18163

CAS No.: 1351761-44-8

Molecular Formula: $C_{19}H_{21}F_4N_5O_3$

Molecular Weight: 443

Target: LRRK2

Pathway: Autophagy

Storage:
Powder	-20°C	3 years	
	4°C	2 years	
In solvent	-80°C	2 years	
	-20°C	1 year	

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (225.73 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2573 mL	11.2867 mL	22.5734 mL
	5 mM	0.4515 mL	2.2573 mL	4.5147 mL
	10 mM	0.2257 mL	1.1287 mL	2.2573 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (5.64 mM); Suspended solution; Need ultrasonic

3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

4. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
   Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	GNE-7915 is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM.
IC50 & Target	IC50: 9 nM[1] (LRRK2)
In Vitro	Maintaining the methoxy/fluoro arrangement at C-2'/C-5' and varying aminoalkyl R1 substitution resultes in single-digit

nanomolar LRRK2 cellular activities for GNE-7915 and compound 19. Expanded Invitrogen kinase profiling (187 kinases) at 0.1 μM for both GNE-7915 (100-fold over LRRK2 Ki) and 19 (250-fold over LRRK2 Ki) resultes in only TTK showing greater than 50% inhibition. Selectivity profiling using the DiscoverX KinomeScan55 competitive binding assay panel, which includes 392 unique kinases, is also performed for GNE-7915 at 0.1 μM. Binding of >50% probe displacement is detected for 10 kinases and of >65% for only LRRK2, TTK, and ALK, further supporting the excellent LRRK2 selectivity for GNE-7915. Cerep receptor profiling, including expanded brain panels, suggestes that GNE-7915 and 19 only inhibit 5-HT$_{2B}$ with >70% inhibition at 10 μM. GNE-7915 and 19 are confirmed to be moderately potent 5-HT$_{2B}$ antagonists in vitro functional assays[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Stem Cell Reports. 2022 Sep 12;S2213-6711(22)00423-4.

- Hum Mol Genet. 2017 Jul 15;26(14):2747-2767.

- bioRxiv. 2020 Apr.

- Programa Oficial de Doctorado en Biomedicina. Universidad de Granada. 5-Jul-2017.

- Harvard Medical School LINCS LIBRARY

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Kavanagh ME, et al. The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorg Med Chem Lett.?2013 Jul 1;23(13):3690-6.

[2]. Estrada AA, et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2012 Nov 26;55(22):9416-33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898   Fax: 609-228-5909   E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA